Skip to main content
NCBI home page
Public Health Reports logoLink to Public Health Reports
. 1993 May-Jun;108(3):294–298.

Where injecting drug users receive HIV counseling and testing.

R O Valdiserri 1, T S Jones 1, G R West 1, C H Campbell Jr 1, P I Thompson 1
PMCID: PMC1403379  PMID: 8497566

Abstract

In 1990, nearly 1.5 million human immunodeficiency virus (HIV) antibody tests were performed at publicly funded sites. Eight percent of those tests were performed for self-identified illegal injecting drug users (IDU). The authors examined data from 28 project areas using a client record data base that permitted an analysis of self-reported risk behavior by type of service delivery site. Among self-identified IDUs, 68 percent of those tested and 82 percent of those found to be seropositive had obtained HIV counseling and testing services in settings other than drug treatment centers. The findings indicate that HIV-prevention programs for IDUs need to be available in various service delivery settings, not just in drug treatment programs. Strong links and cooperation between sites offering HIV counseling and testing and sites providing drug treatment programs are important to preventing HIV transmission to and from IDUs.

Full text

PDF
294

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Battjes R. J., Pickens R. W., Amsel Z. HIV infection and AIDS risk behaviors among intravenous drug users entering methadone treatment in selected U.S. cities. J Acquir Immune Defic Syndr. 1991;4(11):1148–1154. [PubMed] [Google Scholar]
  2. Brown L. S., Jr, Burkett W., Primm B. J. Drug treatment and HIV seropositivity. N Y State J Med. 1988 Mar;88(3):156–156. [PubMed] [Google Scholar]
  3. Calsyn D. A., Saxon A. J., Freeman G., Jr, Whittaker S. Ineffectiveness of AIDS education and HIV antibody testing in reducing high-risk behaviors among injection drug users. Am J Public Health. 1992 Apr;82(4):573–575. doi: 10.2105/ajph.82.4.573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Des Jarlais D. C., Friedman S. R. HIV infection among intravenous drug users: epidemiology and risk reduction. AIDS. 1987 Jul;1(2):67–76. [PubMed] [Google Scholar]
  5. Lampinen T. M., Joo E., Seweryn S., Hershow R. C., Wiebel W. HIV seropositivity in community-recruited and drug treatment samples of injecting drug users. AIDS. 1992 Jan;6(1):123–126. doi: 10.1097/00002030-199201000-00017. [DOI] [PubMed] [Google Scholar]
  6. McCusker J., Koblin B., Lewis B. F., Sullivan J. Demographic characteristics, risk behaviors, and HIV seroprevalence among intravenous drug users by site of contact: results from a community-wide HIV surveillance project. Am J Public Health. 1990 Sep;80(9):1062–1067. doi: 10.2105/ajph.80.9.1062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Nelson K. E., Vlahov D., Cohn S., Odunmbaku M., Lindsay A., Antohony J. C., Hook E. W., 3rd Sexually transmitted diseases in a population of intravenous drug users: association with seropositivity to the human immunodeficiency virus (HIV). J Infect Dis. 1991 Sep;164(3):457–463. doi: 10.1093/infdis/164.3.457. [DOI] [PubMed] [Google Scholar]
  8. Solomon L., Frank R., Vlahov D., Astemborski J. Utilization of health services in a cohort of intravenous drug users with known HIV-1 serostatus. Am J Public Health. 1991 Oct;81(10):1285–1290. doi: 10.2105/ajph.81.10.1285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Valdiserri R. O., West G. R., Moore M., Darrow W. W., Hinman A. R. Structuring HIV prevention service delivery systems on the basis of social science theory. J Community Health. 1992 Oct;17(5):259–269. doi: 10.1007/BF01324356. [DOI] [PubMed] [Google Scholar]

Articles from Public Health Reports are provided here courtesy of SAGE Publications

RESOURCES